Invesco
ALXN

Invesco’s Alexion Pharmaceuticals ALXN Stock Holding History

Invesco’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,052,026
Closed -$193M – 4091
2021
Q2 		$193M Sell
1,052,026
-87,037
-8% -$14.9M 0.05% 541
2021
Q1 		$174M Sell
1,139,063
-9,251
-0.8% -$1.43M 0.05% 546
2020
Q4 		$179M Buy
1,148,314
+96,795
+9% +$12.4M 0.05% 480
2020
Q3 		$120M Buy
1,051,519
+67,198
+7% +$7.25M 0.04% 560
2020
Q2 		$110M Sell
984,321
-235,015
-19% -$25M 0.04% 557
2020
Q1 		$109M Sell
1,219,336
-348,357
-22% -$34.2M 0.05% 472
2019
Q4 		$170M Sell
1,567,693
-1,873,516
-54% -$200M 0.05% 469
2019
Q3 		$337M Buy
3,441,209
+158,519
+5% +$17.9M 0.09% 266
2019
Q2 		$430M Sell
3,282,690
-433,462
-12% -$55.9M 0.11% 213
2019
Q1 		$502M Buy
3,716,152
+42,353
+1% +$5.27M 0.17% 130
2018
Q4 		$358M Sell
3,673,799
-393,420
-10% -$46.5M 0.14% 165
2018
Q3 		$565M Sell
4,067,219
-229,092
-5% -$28.7M 0.18% 127
2018
Q2 		$533M Buy
4,296,311
+408,700
+11% +$47.8M 0.18% 131
2018
Q1 		$433M Sell
3,887,611
-234,823
-6% -$28.1M 0.16% 146
2017
Q4 		$493M Sell
4,122,434
-595,361
-13% -$72.5M 0.18% 129
2017
Q3 		$662M Buy
4,717,795
+313,971
+7% +$42.7M 0.24% 85
2017
Q2 		$536M Buy
4,403,824
+708,900
+19% +$82.5M 0.17% 132
2017
Q1 		$448M Sell
3,694,924
-4,140
-0.1% -$534K 0.15% 153
2016
Q4 		$453M Buy
3,699,064
+609,546
+20% +$74.6M 0.15% 147
2016
Q3 		$379M Buy
3,089,518
+682,824
+28% +$87.9M 0.13% 179
2016
Q2 		$281M Sell
2,406,694
-421,342
-15% -$59.8M 0.1% 223
2016
Q1 		$394M Sell
2,828,036
-366,210
-11% -$53.8M 0.16% 148
2015
Q4 		$609M Sell
3,194,246
-34,485
-1% -$6.02M 0.24% 83
2015
Q3 		$505M Buy
3,228,731
+270,160
+9% +$49.3M 0.21% 96
2015
Q2 		$535M Buy
2,958,571
+306,791
+12% +$52.9M 0.21% 103
2015
Q1 		$460M Sell
2,651,780
-481,450
-15% -$87.1M 0.18% 124
2014
Q4 		$580M Sell
3,133,230
-215,615
-6% -$40M 0.22% 98
2014
Q3 		$555M Sell
3,348,845
-421,756
-11% -$69.3M 0.22% 92
2014
Q2 		$589M Sell
3,770,601
-382,880
-9% -$60.5M 0.23% 90
2014
Q1 		$632M Buy
4,153,481
+612,007
+17% +$97.3M 0.26% 69
2013
Q4 		$471M Buy
3,541,474
+442,215
+14% +$53.1M 0.19% 107
2013
Q3 		$360M Buy
3,099,259
+789,973
+34% +$86.7M 0.16% 136
2013
Q2 		$213M Buy
+2,309,286
New +$223M 0.1% 235

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Invesco's ALXN Position: Q3 2021 in Review

Invesco sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,052,026 shares — an estimated $193M sold.

Invesco first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $662M in Q3 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Invesco reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Invesco sold 1,052,026 Alexion Pharmaceuticals shares in Q3 2021, an estimated $193M.
  • Invesco first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Invesco's Alexion Pharmaceuticals position peaked at $662M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Invesco's 13F filing for Q3 2021, filed 15 Nov 2021.